TAZOCIN POWDER FOR SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM)

から入手可能:

PFIZER CANADA ULC

ATCコード:

J01CR05

INN（国際名）:

PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

投薬量:

2G; 250MG

医薬品形態:

POWDER FOR SOLUTION

構図:

PIPERACILLIN (PIPERACILLIN SODIUM) 2G; TAZOBACTAM (TAZOBACTAM SODIUM) 250MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

11.6 ML

処方タイプ:

Prescription

治療領域:

EXTENDED-SPECTRUM PENICILLINS

製品概要:

Active ingredient group (AIG) number: 0225919001; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2015-04-27

製品の特徴

_ _
_TAZOCIN (Piperacillin Sodium/Tazobactam Sodium)_
_ _
_Page 1 of 43 _
PRODUCT MONOGRAPH
PR
TAZOCIN
®
Piperacillin and Tazobactam powder for injection
2.0g/0.25g, 3g/0.375g, 4.0g/0.5g per vial (as piperacillin sodium and
tazobactam sodium)
Lyophilized Powder for Injection
Antibiotic/ß-lactamase Inhibitor
Pfizer Canada Inc
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Revision:
April 8, 2014
Submission Control No: 171562
®
TM Wyeth Holdings Corporation, Pfizer Canada Inc., Licensee
_ _
_TAZOCIN (Piperacillin Sodium/Tazobactam Sodium)_
_ _
_Page 2 of 43 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................23
SPECIAL HANDLING INSTRUCTIONS
.......................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION
....